It’s been a crucial week for ABIOMED, Inc. (NASDAQ:ABMD); here’s what analysts have to say.

May 29, 2018 - By Ash

ABIOMED, Inc. (NASDAQ:ABMD) LogoInvestors sentiment decreased to 0.95 in 2018 Q1. Its down 0.23, from 1.18 in 2017Q4. It dropped, as 23 investors sold ABIOMED, Inc. shares while 135 reduced holdings. 67 funds opened positions while 83 raised stakes. 36.41 million shares or 0.08% less from 36.44 million shares in 2017Q4 were reported.
Commonwealth Of Pennsylvania School Empls Retrmt System, a Pennsylvania-based fund reported 11,341 shares. Ameritas Prns stated it has 0.18% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Arizona State Retirement Sys stated it has 0.08% in ABIOMED, Inc. (NASDAQ:ABMD). Bnp Paribas Asset Mngmt Hldgs has invested 0.09% in ABIOMED, Inc. (NASDAQ:ABMD). New York State Teachers Retirement invested in 79,600 shares or 0.06% of the stock. Frontier Cap Co Lc has 36,009 shares for 0.08% of their portfolio. Intersect Cap Ltd Liability Corporation holds 0.11% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 735 shares. Moors & Cabot holds 0.07% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 1,785 shares. Da Davidson Communication has 967 shares. 20,312 are held by Financial Bank Of Montreal Can. Eqis Cap Management has invested 0.02% in ABIOMED, Inc. (NASDAQ:ABMD). Cibc Bancshares Usa reported 1,345 shares. 60 were reported by Vantage Inv Advisors Lc. Cubist Systematic Strategies Ltd Co holds 0.29% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 16,800 shares. 77,503 are held by Retirement Sys Of Alabama.

Since February 20, 2018, it had 0 buys, and 5 selling transactions for $31.65 million activity. 17,500 shares were sold by Howley Michael G, worth $6.09M. $7.93M worth of stock was sold by BOLT WILLIAM J on Monday, May 7. PUHY DOROTHY E also sold $4.70M worth of ABIOMED, Inc. (NASDAQ:ABMD) shares. 21,890 shares valued at $7.52M were sold by SUTTER MARTIN P on Tuesday, May 8.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed had 12 analyst reports since December 21, 2017 according to SRatingsIntel. The rating was maintained by Morgan Stanley on Friday, February 2 with “Equal-Weight”. The rating was maintained by Jefferies on Thursday, February 1 with “Buy”. The firm has “Buy” rating given on Friday, February 2 by Guggenheim. The firm has “Buy” rating given on Friday, February 2 by Stephens. The rating was maintained by Piper Jaffray with “Buy” on Thursday, January 4. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Equal-Weight” rating given on Tuesday, May 1 by Morgan Stanley. The rating was maintained by SunTrust with “Buy” on Friday, February 16. The stock has “Buy” rating by Stephens on Monday, April 9. Jefferies maintained the shares of ABMD in report on Thursday, December 21 with “Buy” rating. Piper Jaffray maintained the shares of ABMD in report on Thursday, February 1 with “Buy” rating. Below is a list of ABIOMED, Inc. (NASDAQ:ABMD) latest ratings and price target changes.

01/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $259 New Target: $320 Maintain
09/04/2018 Broker: Stephens Rating: Buy New Target: $300.0000 Maintain
04/04/2018 Broker: Goldman Sachs Rating: Buy New Target: $332 Initiates Coverage On
16/02/2018 Broker: SunTrust Rating: Buy New Target: $370.0 Maintain
02/02/2018 Broker: Stephens Rating: Buy New Target: $274.0 Maintain
02/02/2018 Broker: Leerink Swann Rating: Buy New Target: $300.0
02/02/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $204 New Target: $259 Maintain
02/02/2018 Broker: Guggenheim Rating: Buy New Target: $280.0 Maintain
01/02/2018 Broker: Jefferies Rating: Buy New Target: $300.0 Maintain
01/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $300.0 Maintain

The stock decreased 0.05% or $0.18 during the last trading session, reaching $394.28. About 388,427 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 190.17% since May 29, 2017 and is uptrending. It has outperformed by 177.60% the S&P500.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $17.50 billion. It also provides continuum of care to heart failure patients. It has a 197.83 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: ASCO Presentations In The Spotlight” on May 26, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” published on May 11, 2018, Seekingalpha.com published: “PRAH +3% on MidCap 400 move; ABMD to S&P 500” on May 25, 2018. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Seekingalpha.com and their article: “ABIOMED (ABMD) Q4 2018 Results – Earnings Call Transcript” published on May 03, 2018 as well as Benzinga.com‘s news article titled: “Abiomed Earnings Outlook” with publication date: May 02, 2018.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.